¿ËÈÕ£¬AGGAME£¨¼ò³Æ¡°AGGAMEÒ©Òµ¡±£©Á¢ÒìÒ©¿Ø¹É×Ó¹«Ë¾¸£½¨¹ãÉúÖÐÁØÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾µÄÒÒ¸ÎÖÎÁÆÁ¢ÒìÒ©GST-HG141£¨Ó¢ÎÄͨÓÃÃû ¡°Neracorvir¡±£¬ÖÐÎÄͨÓÃÃû ¡°ÄÎÈð¿ÉΤ¡±£©µÄ¢ñbÆÚÁÙ´²ÊÔÑéЧ¹ûÒѾÀֳɽÒÏþ¡£
GST-HG141ÄÎÈð¿ÉΤÊÇÐÂÐÍÒҸν¹µãÂѰ׻òºËÒ¿ǵ÷Àí¼Á£¬ÊôÓÚȫлúÖÆµÄÔÚÑп¹ÒҸβ¡¶¾Ò»ÀàÐÂÒ©¡£Ëüͨ¹ýÆæÒìµÄ»úÖÆ£¬ÓÐÓõ÷ÀíÒҸβ¡¶¾½¹µãÂѰ׵Ĺ¹Ï󣬽ø¶øÓ°Ï첡¶¾µÄ¸´ÖÆÀú³Ì£¬ÎªÒҸεÄÁÙ´²ÖÎÓúÌṩÁËеĽâ¾ö¼Æ»®¡£2024Äê11Ô£¬GST-HG141ÄÎÈð¿ÉΤµÄÁÙ´²Ñо¿Ð§¹û±»¹ú¼ÊȨÍþרҵ»ú¹¹¡ªÃÀ¹ú¸Î²¡Ñо¿Ð»á£¨AASLD£©×÷Ϊ×îÐÂÍ»ÆÆÕªÒª£¨Late-breaking Abstract£©ÐÎʽÔÚAASLDÄê»áÉϾÙÐÐչʾ£»2024Äê12Ô£¬GST-HG141ÄÎÈð¿ÉΤ±»¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾ÖÒ©Æ·ÉóÆÀÖÐÐÄÄÉÈëÍ»ÆÆÐÔÖÎÁÆÆ·ÖÖÃûµ¥£¬Î´À´ÓÐÍû³ÉΪȫÇòÒҸο¹²¡¶¾ÖÎÁÆÀï³Ì±®Ê½µÄÁ¢ÒìÒ©¡£
¸ÃÒ©Îï¢ñÆÚÁÙ´²ÊÔÑéÔÚ¼ªÁÖ´óѧµÚÒ»Ò½Ôº£¨ÒÔϼò³Æ£º¼ª´óÒ»Ôº£©Ò»ÆÚÒ©ÎïÁÙ´²ÊÔÑ鲡·¿¿ªÕ¹£¬ÓÉÅ£¿¡Ææ½ÌÊںͶ¡ÑÞ»ª½ÌÊÚÖ÷³ÖÍê³É²¢×÷ΪÅäºÏͨѶ×÷Õß½«Ñо¿Ð§¹û½ÒÏþÔÚ¡¶Virology Journal¡·ÔÓÖ¾£¬2024Äê12ÔÂ20ÈÕÕýʽÏßÉϹûÕæ£¬ÎÄÕ±íÌâΪ¡¶Safety, pharmacokinetics, and antiviral effficacy of the novel capsid assembly modulator GST-HG141 in patients with chronic hepatitis B: a phase 1 trial with a randomized,placebo-controlled design¡·¡£
¸ÃÑо¿Îª¶àÖÐÐÄ¡¢Ëæ»ú¡¢Ë«Ã¤¡¢Î¿½å¼Á±ÈÕյĶà¼ÁÁ¿¡¢¶à´Î¸øÒ©µÄÄÍÊÜÐÔ¡¢Ò©´ú¶¯Á¦Ñ§ºÍҩЧѧµÄ¢ñbÆÚÁÙ´²ÊÔÑéÑо¿£¬Ö¼ÔÚÆÀ¼ÛGST-HG141ƬÔÚÂýÐÔÒÒÐ͸ÎÑ×»¼ÕßÖжà´Î¸øÒ©µÄÄÍÊÜÐÔ¡¢ÆðԴҩЧѧºÍÒ©´ú¶¯Á¦Ñ§ÌØÕ÷¡£
Ñо¿¹²ÄÉÈë30ÀýÂýÐÔÒÒÐ͸ÎÑ×(CHB£©³õÖλ¼Õß×÷ΪÊÜÊÔÕߣ¬¹²ÉèÖÃ3¸öGST-HG141¼ÁÁ¿×飬»®·ÖΪ25 mg BID£¨µÚÒ»×飩¡¢50 mg BID£¨µÚ¶þ×飩¡¢100 mg BID£¨µÚÈý×飩¼ÁÁ¿×飬ÿ×é¸÷ÄÉÈë10ÀýÊÜÊÔÕߣº8Àý½ÓÊÜÊÔÑéÒ©Î2Àý½ÓÊÜο½å¼Á¡£¸÷¼ÁÁ¿×éÒ»Á¬¸øÒ©28Ì죬µÚ1Ìì-µÚ27ÌìÌìÌì¸øÒ©2´Î£¬¸øÒ©¾àÀë12Сʱ£¬µÚ28ÌìÔçÉϸøÒ©Ò»´Î£¬²Íºó¸øÒ©¡£
Ñо¿Ð§¹ûÏÔʾGST-HG141 ÔÚËùÓмÁÁ¿Ï¾ùÌåÏÖ³öÓÅÒìµÄÇå¾²ÐÔºÍÄÍÊÜÐÔ
ÔÚ28ÌìÓÃҩʱ´úûÓÐÊÜÊÔÕß·ºÒòÓÉÒ©Îï²»Á¼·´Ó¦ (ADR) µ¼ÖµÄéæÃü¡¢ÑÏÖØ²»Á¼ÊÂÎñ»òÍ£Ò©µÄÇéÐΣ¬Î´±¬·¢¼¡ËáÁ×ËἤøÔö¸ßµÄ²»Á¼·´Ó¦¡£¸÷¼ÁÁ¿×é²»Á¼·´Ó¦±¬·¢ÂÊÎÞÏÔ×Ųî±ð£¬ÇÒÓëο½å¼Á×éÎÞͳ¼ÆÑ§²î±ð¡£Î´¼ûÓë¼ÁÁ¿Ïà¹ØÐÔ²»Á¼·´Ó¦£¬ËùÓв»Á¼ÊÂÎñ¾ùΪÇá¶È£¬±¬·¢ÂʺÍÑÏÖØË®Æ½²¢Î´Ëæ¼ÁÁ¿ÔöÌí¶øÉý¸ß¡¢¼ÓÖØ¡£³£¼û²»Á¼ÊÂÎñ°üÀ¨ÖÐÐÔÁ£Ï¸°û¼ÆÊýïÔÌ£¨12.5%£©¡¢°×ϸ°û¼ÆÊýïÔÌ£¨8.3%£©¡¢µÍÁ×Ѫ֢£¨8.3%£©¡¢±û°±Ëá°±»ù×ªÒÆÃ¸Ë®Æ½Éý¸ß£¨8.3%£©ºÍÌìÃŶ¬°±Ëá°±»ù×ªÒÆÃ¸Ë®Æ½Éý¸ß£¨8.3%£©¡£
Ñо¿ÒÔΪ£¬ÔÚÂýÐÔÒÒÐ͸ÎÑ×»¼ÕßÖУ¬ GST-HG141µÄ¼ÁÁ¿×ÝÈ»¸ß´ï100mg£¬ ÆäÇå¾²ÐÔÈÔ¿É¿¿£¬ÎÞÏÔ×ŵÄÑÏÖØÇå¾²ÐÔÎÊÌâ¡£´ó´ó¶¼²»Á¼ÊÂÎñΪÇá¶ÈÖÁÖжȣ¨1 ¼¶»ò 2 ¼¶£©£¬ÇÒ±¬·¢ÆµÂÊ»òÑÏÖØË®Æ½¶¼Ã»ÓÐÏÔ×ŵļÁÁ¿Ïà¹ØÇ÷ÊÆ¡£Î´·¢Ã÷ת°±Ã¸Ë®Æ½Éý¸ßÓйصÄÑÏÖØ²»Á¼·´Ó¦¡£
GST-HG141¾ßÓкÜÇ¿µÄ¿¹²¡¶¾»îÐÔ£¬CHB»¼ÕßÖÎÁÆ28Ìì¿É´ó·ù½µµÍHBV DNA ºÍ HBV pgRNA µÄˮƽ
ÔÚÖÎÁÆÊ±´ú£¬25mg BID×é¡¢50mg BID×é¡¢100mg BID 3¸ö¼ÁÁ¿×éÊÜÊÔÕßµÄHBV DNA ˮƽ¾ùÒ»Á¬½µµÍ£¬ÔÚµÚ 29 ÌìµÖ´ï×îµÍˮƽ£¬Óë»ùÏßÏà±ÈµÄ½µµÍ·ù¶È»®·ÖΪ -3.01 (0.47) log10 IU/mL¡¢-2.92 (1.26) log10 IU/mL¡¢-3.43 (0.55)log10 IU/mL£¬25mg BID×é¡¢50mg BID×éHBV DNAϽµË®Æ½ÎÞÏÔ×Ųî±ð£¬100mg BID×éHBV DNAϽµË®Æ½ÂÔÓÅÓÚǰ2¸ö¼ÁÁ¿×顣ͣҩºó5Ìì·ºÆð²î±ðˮƽµÄ·´µ¯£¬µ«Ëæ×ÅÖÎÁƼÁÁ¿Éý¸ß£¬·´µ¯ËÙÂʽµµÍ¡£
3¸ö¼ÁÁ¿×éÊÜÊÔÕßµÄHBV pgRNA¾ù½Ï»ùÏß½µµÍ£¬½µµÍ·ù¶ÈÏÔ×ÅÓÅÓÚο½å¼Á×飬ÔÚµÚ29Ììʱ£¬25mg BID×é¡¢50mg BID×é¡¢100mg BID×éÓë»ùÏßÏà±ÈHBV pgRNAµÄ½µµÍ·ù¶È»®·ÖΪ-1.71 (1.003) log10 IU/mL¡¢-1.93 (0.899) log10 IU/mL¡¢-2.37 (0.784) log10 IU/mL£¬½µµÍ·ù¶È¾ßÓÐÒ»¶¨¼ÁÁ¿Ïà¹ØÐÔ¡£
¸÷¼ÁÁ¿×éHBeAg¾ù½Ï»ùÏßϽµ£¬Ï½µË®Æ½ÏÔ×ÅÓÅÓÚο½å¼Á×飬25mg BID×é¡¢50mg BID×é¡¢100mg BID×éÓë»ùÏßÏà±ÈHBeAgµÄ½µµÍ·ù¶È»®·ÖΪ-0.08 (0.119) log10 U/mL¡¢-0.05 (0.063) log10 U/mL¡¢-0.09 (0.099) log10 U/mL£¬¸÷¼ÁÁ¿×éϽµË®Æ½ÎÞÏÔ×Ųî±ð¡£¸÷¼ÁÁ¿×éHBcrAg½Ï»ùÏß¾ùϽµ£¬Ï½µË®Æ½ÏÔ×ÅÓÅÓÚο½å¼Á×飬ÔÚµÚ29Ììʱ£¬25mg BID×é¡¢50mg BID×é¡¢100mg BID×éHBcrAg½Ï»ùÏ߯½¾ùÖµ£¨±ê×¼²î£©½µ·ù»®·ÖΪ-0.25 log10 IU/mL¡¢-0.30log10 IU/mL¡¢-0.25 log10 IU/mL£¬¸÷¼ÁÁ¿×éϽµË®Æ½ÎÞÏÔ×Ųî±ð¡£
Ò©´ú¶¯Á¦Ñ§ÆÊÎöÅú×¢£¬GST-HG141ѪҩŨ¶ÈÔÚ25~50mg BID¹æÄ£ÄÚ³ÊÏßÐÔ¹ØÏµÇ÷ÊÆ£¬ÇҸùæÄ£Ä򵀮½¾ù¹ÈŨ¶È×ãÒÔÁýÕÖÂѰ×ÍŽáµ÷½âºóµÄEC50
25mg BID¡¢50mg BIDºÍ100mg BIDÒ»Á¬¸øÒ©28Ì죬Ѫ½¬ÖÐGST-HG141ÖÐλ´ï·åʱ¼äΪ3.0 ~ 3.5Сʱ£¨µÚ1Ì죩ºÍ2.0~ 3.5Сʱ£¨µÚ28Ì죩£¬µÚ 8 Ìì µÖ´ïÎÈ̬£¬GST-HG141ÔÚÌåÄÚÓÐÉÔ΢µÄÐî»ý¡£µÚ 28 Ì죬25mg BID¡¢50mg BIDºÍ100mg BID ×éÊÜÊÔÕßµÄGST-HG141ƽ¾ù¹ÈŨ¶È»®·Ö±ÈÆäÂѰ×ÍŽáµ÷½âºóµÄ HBV DNA EC50£¨17ng/ mL£©¸ß 4.4¡¢11.1 ºÍ 14.6 ±¶¡£
AGGAMEÒ©Òµ¸ß¶ÈÖØÊÓGST-HG141ÄÎÈð¿ÉΤµÄÑз¢ÊÂÇ飬×èÖ¹±¾¸åÐû²¼ÈÕ£¬AGGAMEÒѾÍê³ÉÁË´ÓÁÙ´²Ç°Ñо¿µ½IIÆÚÁÙ´²ÊÔÑéµÄËùÓÐÊÂÇ飬ÇÒIIÆÚÁÙ´²ÊÔÑéµÄÑо¿×ܽᱨ¸æÏÔʾGST-HG141ÄÎÈð¿ÉΤ¹ØÓÚÂýÐÔÒÒÐ͸ÎÑ׵Ͳ¡¶¾ÑªÖ¢»¼Õß¾ßÓÐÓÅÒìµÄÇå¾²ÐÔºÍÏÔÖøÒ©Ð§£¬¶ÔHBV DNAµÄÒÖÖÆÐ§¹ûÏÔÖøÓÅÓÚÏÖÔÚÁÙ´²ÖÎÁÆÍƼöºËÜÕ£¨ËᣩÀàËÆÎïµ¥Ò©ÖÎÁƱÈÕÕ×飬ÔÚÒҸλ¼ÕßÉÏÈ·Ö¤ÁËÆäÔÚºËÜÕ£¨ËᣩÀàÒ©ÎïÖÎÁÆ»ù´¡ÉϽøÒ»²½ÒÖÖÆHBV DNA¸´ÖƺÍDZÔںĽßcccDNAµÄ×÷Óã¬ÁÙ´²Ñо¿µÖ´ïÔ¤ÆÚÄ¿µÄ£¬Êý¾ÝÓÅÒì¡£¹«Ë¾½«¼ÌÐø±ü³Ö¿ÆÑ§¡¢ÑϽ÷µÄÑз¢Ì¬¶È£¬¼ÓËÙÐÂÒ©Ñз¢Àú³Ì£¬ÎªÈ«ÇòÒҸλ¼ÕßÌṩ¸ü¶à¡¢¸üºÃµÄÖÎÁÆÑ¡Ôñ¡£
²Î¿¼ÎÄÏ×
Wu et al. Safety, pharmacokinetics, and antiviral efffcacy of the novel capsid assembly modulator GST-HG141 in patients with chronic hepatitis B: a phase 1 trial with a randomized,placebo-controlled design.Virology Journal (2024) 21:328 https://doi.org/10.1186/s12985-024-02584-8


Ãö¹«Íø°²±¸ 35092602000113ºÅ